Med (New York, N.Y.) - JoVE Visualize

Showing results (611-620 of 866) with videos related to

Pageof 87

Sort By:

Med (New York, N.Y.)|August 14, 2026

LSD therapy: A few hundred meters from where it beganFelix Müller, Anna M Becker, Christopher Böhlke, et al.

Med (New York, N.Y.)|August 14, 2026

Gone but not forgotten: CAR-NK cells leave a lasting mark on autoimmunityRejeena Shrestha, Rafet Basar

Med (New York, N.Y.)|September 14, 2026

N-of-1 investigational study of a novel antisense oligonucleotide drug in CHCHD10-related ALS shows early signs of efficacyMargot A Cousin, Aditi I Dagli, Laurence Mignon, et al.

Med (New York, N.Y.)|September 18, 2026

Pregnancy-associated cardiac complicationsSarah Thordsen, Zoltan Arany

Med (New York, N.Y.)|September 9, 2026

Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003)Fei Xiao, Liru Wang, Fei Li, et al.

Med (New York, N.Y.)|September 11, 2026

Generalized myasthenia gravis: Clinical trials to watchSarah Hoffmann, Paolo Doksani, James F Howard

Med (New York, N.Y.)|October 9, 2026

Q&A with Mihaela van der Schaar

Med (New York, N.Y.)|October 13, 2026

Cancer plasticity and histological transformation as adaptive resistance mechanisms in precision oncologyNick A Kuburich, Mohamed A Gouda, Breanna R Demestichas, et al.

Med (New York, N.Y.)|October 14, 2026

Tumor DNA methylation subtypes and expression levels of CFISH predict response and overall survival to immunochemotherapyHannah S Fuchs, Phil Xie, Sabrina A James, et al.

Med (New York, N.Y.)|February 12, 2025

KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancerMarjolein F Lansbergen, Mark P G Dings, Jan Koster, et al.

Pageof 87

Showing results (611-620 of 866) with videos related to

Sort By:

Pageof 87

Med (New York, N.Y.)|August 14, 2026

LSD therapy: A few hundred meters from where it beganFelix Müller, Anna M Becker, Christopher Böhlke, et al.

Med (New York, N.Y.)|August 14, 2026

Gone but not forgotten: CAR-NK cells leave a lasting mark on autoimmunityRejeena Shrestha, Rafet Basar

Med (New York, N.Y.)|September 14, 2026

N-of-1 investigational study of a novel antisense oligonucleotide drug in CHCHD10-related ALS shows early signs of efficacyMargot A Cousin, Aditi I Dagli, Laurence Mignon, et al.

Med (New York, N.Y.)|September 18, 2026

Pregnancy-associated cardiac complicationsSarah Thordsen, Zoltan Arany

Med (New York, N.Y.)|September 9, 2026

Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003)Fei Xiao, Liru Wang, Fei Li, et al.

Med (New York, N.Y.)|September 11, 2026

Generalized myasthenia gravis: Clinical trials to watchSarah Hoffmann, Paolo Doksani, James F Howard

Med (New York, N.Y.)|October 9, 2026

Q&A with Mihaela van der Schaar

Med (New York, N.Y.)|October 13, 2026

Cancer plasticity and histological transformation as adaptive resistance mechanisms in precision oncologyNick A Kuburich, Mohamed A Gouda, Breanna R Demestichas, et al.

Med (New York, N.Y.)|October 14, 2026

Tumor DNA methylation subtypes and expression levels of CFISH predict response and overall survival to immunochemotherapyHannah S Fuchs, Phil Xie, Sabrina A James, et al.

Med (New York, N.Y.)|February 12, 2025

KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancerMarjolein F Lansbergen, Mark P G Dings, Jan Koster, et al.

Pageof 87